A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

• ClinicalTrials.gov Identifier: NCT05475925
• Recruitment Status: Recruiting
• First Posted: July 27, 2022
• Last Update Posted: October 27, 2023
• Sponsor: Dren Bio
• Collaborator: Novotech
• Information provided by (Responsible Party): Dren Bio

Tracking Information

• First Submitted Date: July 21, 2022
• First Posted Date: July 27, 2022
• Last Update Posted Date: October 27, 2023
• Actual Study Start Date: July 13, 2022
• Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: December 7, 2022)

• Part A: Safety and Tolerability. To determine the incidence and severity of adverse events as assessed by CTCAE v5.0. [ Time Frame: Up to 25 months ]
• Part A: Safety and Tolerability. To determine the incidence and severity of dose limiting toxicities (DLTs) as defined by protocol specified DLT criteria. [ Time Frame: During First 28 days (Cycle 1) ]
• Part A: To determine potential pharmacologically optimized dose/regimen for DR-01 in LGL leukemia and cytotoxic lymphoma populations as determined using an integrated assessment of efficacy, safety, PK/PD, and exposure-response relationships. [ Time Frame: Up to 6 months ]
• Part B: Overall Response Rate (ORR), defined as the proportion of subjects with Complete Response (CR) or Partial Response (PR) based on disease-specific response criteria. [ Time Frame: Up to 24 months ]

Original Primary Outcome Measures (submitted: July 25, 2022)

• Part A: Safety and Tolerability. To determine the incidence and severity of adverse events as assessed by CTCAE v5.0. [ Time Frame: Up to 25 months ]
• Part A: Safety and Tolerability. To determine the incidence and severity of dose limiting toxicities (DLTs) as defined by protocol specified DLT criteria. [ Time Frame: During First 28 days (Cycle 1) ]
• Part A: Max tolerated dose of DR-01 (if applicable). [ Time Frame: Up to 1 month ]
• Part A: Recommended Phase 2 dose (RP2D) of DR-01 in LGL leukemia and cytotoxic lymphoma populations as determined by integrated assessment of target engagement/attainment, efficacy, safety, PK/PD, and exposure-response relationships. [ Time Frame: Up to 6 months ]
• Part B: Overall Response Rate (ORR), defined as the proportion of subjects with Complete Response (CR) or Partial Response (PR) based on disease-specific response criteria. [ Time Frame: Up to 24 months ]

• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
• Official Title: A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
• Brief Summary: This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 1; Phase 2
• Study Design: Allocation: Non-Randomized; Intervention Model: Sequential Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• LGLL - Large Granular Lymphocytic Leukemia
• Primary Cutaneous T-Cell Lymphoma - Category
• Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma
• Hepatosplenic T-cell Lymphoma
• Subcutaneous Panniculitis-Like T-Cell Lymphoma
• Aggressive NK Cell Leukemia
• Systemic EBV1 T-cell Lymphoma, if CD8 Positive
• Hydroa Vacciniforme-Like Lymphoproliferative Disorder
• Extranodal NK/T Cell Lymphoma, Nasal Type
• Enteropathy-Associated T-Cell Lymphoma
• Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
• Indolent Chronic Lymphoproliferative Disorder (CLPD) (CD8+ or NK Derived) of the GI Tract
• Other CD8+/NK Cell Driven Lymphoma Not Listed Above

Intervention

Drug: DR-01

DR-01 is a non-fucosylated, human immunoglobulin G1 (IgG1) monoclonal antibody.

Study Arms

• Experimental: Part A Dose Escalation 1 mg/kg of DR-01
  Subjects in this arm will initially receive 1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 6 mg/kg) thereafter for up to 25 cycles total.
  Intervention: Drug: DR-01
• Experimental: Part A Dose Escalation 3 mg/kg of DR-01
  Subjects in this arm will initially receive 3 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
  Intervention: Drug: DR-01
• Experimental: Part A Dose Escalation 6 mg/kg of DR-01
  Subjects in this arm will initially receive 6 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
  Intervention: Drug: DR-01
• Experimental: Part A Dose Escalation 10 mg/kg of DR-01
  Subjects in this arm will initially receive 10 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 10 mg/kg) thereafter for up to 25 cycles total.
  Intervention: Drug: DR-01
• Experimental: Part A Dose De-escalation 0.3 to <1 mg/kg of DR-01
  This cohort would only be triggered should a DLT occur at Dose Level 1 or if recommended by the Safety Review Committee. Subjects in this arm would initially receive 0.3 to <1 mg/kg at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing (up to 3 mg/kg) thereafter for up to 25 cycles total.
  Intervention: Drug: DR-01
• Experimental: Part B Dose Expansion (Cohort B1) Optimized Dose/Regimen of DR-01
  Subjects in this arm will receive the pharmacologically optimized dose/regimen for LGL leukemia subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
  Intervention: Drug: DR-01
• Experimental: Part B Dose Expansion (Cohort B2) Optimized Dose/Regimen of DR-01
  Subjects in this arm will receive the pharmacologically optimized dose/regimen for cytotoxic lymphoma subjects determined in Part A. Depending on the selected dose/regimen, subjects will receive target dose at either the Primary regimen (bi-weekly dosing for fist month), Secondary regimen (doses at Days 1, 8, 15, 29 during first month), or Tertiary regimen (dosing days 1-5, 15, 29 during first month), followed by monthly dosing thereafter for up to 25 doses total.
  Intervention: Drug: DR-01

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: July 25, 2022): 69
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: December 2025
• Estimated Primary Completion Date: December 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria (All Subjects):

1. ≥18 years of age.
2. Able to understand and comply with protocol-required study procedures and voluntarily sign a written informed consent document.
3. Sufficient key organ performance and coagulation.
4. Female subjects of childbearing potential (postmenarcheal, has an intact uterus and at least one ovary, and is <1 year postmenopausal) must agree to use a highly effective method of contraception from enrollment through at least 12 months after last dose of DR-01.

5. Male subjects must agree to use acceptable effective method(s) of contraception.

   Subjects with LGLL must also meet inclusion criteria 6 and 7.

6. Must have discontinued at least one prior line of systemic therapy.

7. Additional immunophenotypic criteria must be met.

   Disease-specific Inclusion Criteria (Cytotoxic Lymphomas):

   Subjects with cytotoxic lymphomas must also meet inclusion criteria 8,9, and 10.

8. Subjects must have failed at least two prior systemic regimens.
9. Availability of post-progression tissue sample or willingness to consent to a baseline biopsy.
10. Histologically confirmed diagnosis of a cytotoxic lymphoma by a hematopathologist (according to the WHO 2016 classification [Swerdlow 2016]).
11. For Part A only, evaluable disease is acceptable.
12. For Part B2 only:

Subjects must have radiographically measurable disease to be assessed by Lugano criteria. Subjects with primary cutaneous variants must have at least 1 measurable lesion that is evaluable using the Olsen criteria (Olsen 2021) or leukemic involvement that can be evaluated using a modified TPLL response criteria (Staber 2019).

Subjects with hepatosplenic disease or other variants that do not have measurable disease by Lugano criteria (Cheson 2014) may be eligible upon discussion with the Medical Monitor if they have identifiable leukemic involvement in BM or peripheral blood (meeting the CD8+ cytotoxic phenotype definition) that can be evaluated for response using a modified TPLL response criteria (Staber 2019), or skin involvement that can be evaluated using Olsen criteria (Olsen 2021).

Exclusion Criteria:

Disease-specific Exclusion Criteria; LGLL and ANKL:

1. A reactive LGL lymphocytosis to a viral infection or LGL associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).

   The following exclusion criteria apply to all subjects:

2. Active systemic infection or severe localized infection requiring systemic antibiotics, antivirals or antifungals.
3. Active or suspected malignant central nervous system involvement.
4. Life-threatening, severe complications of malignancy (e.g., uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation).
5. Active known second malignancy.
6. Infection with human immunodeficiency virus (HIV) type 1 or 2 (HIV-1 or HIV-2).
7. Hepatitis B infection (hepatitis B virus surface antigen [HBsAg] positive), or hepatitis C (hepatitis C virus [HCV] antibody positive, confirmed by HCV ribonucleic acid). Subjects with HCV with undetectable virus after treatment are eligible.
8. History of clinically significant cardiac disease or congestive heart failure greater than New York Heart Association (NYHA) Class II.
9. Use of systemic corticosteroids (e.g., >5 mg/day prednisone or equivalent for subjects with LGL leukemia (subjects on 20 mg prednisone or equivalent to treat LGL leukemia must be weaned within 28 days post C1D1 to 5 mg) and >10 mg/day prednisone or equivalent for subjects with cytotoxic lymphoma) within 15 days (except for prophylaxis for radiodiagnostic contrast reactions), or other non-biological immunosuppressive drugs within 15 days, prior to C1D1. Patients on stable prednisone ≤10 mg for documented rheumatologic/autoimmune conditions are exempted from this requirement.
10. Any condition requiring hormonal therapy (except for contraception, hormone replacement therapy and hormonal prophylaxis for a prior malignancy).
11. Any other medical or psychiatric condition, or laboratory abnormality that would increase the risk associated with study participation, in the opinion of the Investigator or Medical Monitor.
12. Toxicities from previous anticancer therapies must have resolved to baseline levels or to Grade 1 (except for alopecia, peripheral neuropathy, or hematologic parameters meeting inclusion criteria).
13. Autologous HSCT within 40 days of C1D1, allogeneic HSCT within 90 days
14. Any immunosuppressive therapy for GVHD for subjects who are post allogeneic HSCT.
15. Major surgery within 28 days of C1D1 (requires more than local anesthesia or plexus blockade).

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: Dren Central Contact; 415-737-5277; clinops@drenbio.com

• Listed Location Countries: Australia, France, Spain, United States

Administrative Information

• NCT Number: NCT05475925
• Other Study ID Numbers: DR-01-ONC-001
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Dren Bio
• Original Responsible Party: Same as current
• Current Study Sponsor: Dren Bio
• Original Study Sponsor: Same as current
• Collaborators: Novotech

Investigators

• Study Director: Kimberley Dilley, MD, MPH; Dren Bio

• PRS Account: Dren Bio
• Verification Date: October 2023